Limits...
Androgen deprivation and cognition in prostate cancer.

Salminen E, Portin R, Korpela J, Backman H, Parvinen LM, Helenius H, Nurmi M - Br. J. Cancer (2003)

Bottom Line: During longitudinal testing of the AD group, no impairment in cognitive performances was found.Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs.These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Turku University Hospital, Kiinamyllynkatu 4-8, Fin-20520 Turku, Finland. eevsal@utu.fi

ABSTRACT
Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed software was used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL). During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was observed in object recall (immediate, P=0.035; delayed, P<0.001), and in semantic memory (P=0.037). In QoL, impairment in physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

Show MeSH

Related in: MedlinePlus

Cognitive performance of patients during AD therapy from baseline through 6 and 12 months in three memory tests; statistically significant improvement, marked as *.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376935&req=5

fig2: Cognitive performance of patients during AD therapy from baseline through 6 and 12 months in three memory tests; statistically significant improvement, marked as *.

Mentions: During the period of 12 months on AD, some changes emerged in memory performances compared to the baseline values (Table 1). The patients improved their performances in episodic memory (immediate recall of objects, P=0.035, significant change for the first 6 months and delayed recall P<0.001, significant change for the whole test period) and in semantic memory (similarities, P=0.037, significant change for the latter half of the test period (Figure 2Figure 2


Androgen deprivation and cognition in prostate cancer.

Salminen E, Portin R, Korpela J, Backman H, Parvinen LM, Helenius H, Nurmi M - Br. J. Cancer (2003)

Cognitive performance of patients during AD therapy from baseline through 6 and 12 months in three memory tests; statistically significant improvement, marked as *.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376935&req=5

fig2: Cognitive performance of patients during AD therapy from baseline through 6 and 12 months in three memory tests; statistically significant improvement, marked as *.
Mentions: During the period of 12 months on AD, some changes emerged in memory performances compared to the baseline values (Table 1). The patients improved their performances in episodic memory (immediate recall of objects, P=0.035, significant change for the first 6 months and delayed recall P<0.001, significant change for the whole test period) and in semantic memory (similarities, P=0.037, significant change for the latter half of the test period (Figure 2Figure 2

Bottom Line: During longitudinal testing of the AD group, no impairment in cognitive performances was found.Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs.These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Turku University Hospital, Kiinamyllynkatu 4-8, Fin-20520 Turku, Finland. eevsal@utu.fi

ABSTRACT
Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed software was used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL). During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was observed in object recall (immediate, P=0.035; delayed, P<0.001), and in semantic memory (P=0.037). In QoL, impairment in physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

Show MeSH
Related in: MedlinePlus